Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma

Background: Hepatocellular carcinoma (HCC) is a lethal malignancy lacking effective treatment. The Cyclin-dependent kinases 4/6 (CDK4/6) and PI3K/AKT signal pathways play pivotal roles in carcinogenesis and are promising therapeutic targets for HCC. Here we identified a new CDK4/6 and PI3K/AKT multi...

Full description

Bibliographic Details
Main Authors: Zhong-Kun Xia, Wei Wang, Jian-Ge Qiu, Xi-Nan Shi, Hong-Jian Li, Rong Chen, Kun-Bin Ke, Chao Dong, Ying Zhu, Shi-Guo Wu, Rong-Ping Zhang, Zhuo-Ran Meng, Hui Zhao, Peng Gu, Kwong-Sak Leung, Man-Hon Wong, Xiao-Dong Liu, Feng-Mei Zhou, Jian-Ying Zhang, Ya-Ting Yao, Si-Jia Wang, Chun-Yang Zhang, Yan-Ru Qin, Marie Chia-mi Lin, Bing-Hua Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Pharmacology
Subjects:
aminoquinol
hepatocellular carcinoma
CDK4/6
RB
PI3K
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.691769/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.691769/full

Similar Items